Do prodrugs deliver?

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 5, 2007, Pages 550-559

  Smith, D A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antibody; Cancer therapy; Lipophilicity; Polar surface area

Indexed keywords

ACICLOVIR; CANDESARTAN; CANDESARTAN HEXETIL; CANDOXATRIL; CANDOXATRILAT; CAPTOPRIL; CARBENICILLIN; CARINDACILLIN; DEXFENFLURAMINE; ENALAPRIL; ENALAPRILAT; FAMCICLOVIR; FENFLURAMINE; FLUCONAZOLE; FOSFLUCONAZOLE; FOSINOPRIL; FOSINOPRILAT; GABAPENTIN; GAPAPENTIN ENACARBIL; METHOTREXATE DERIVATIVE; OMEPRAZOLE; OSELTAMIVIR; OSELTAMIVIR DESETHYL ESTER; PENCICLOVIR; PHENYLALANINE GABAPENTIN; PRODRUG; RAMIPRIL; RAMIPRILAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; XP 13512;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; HUMAN; MYCOSIS; PHYSICAL CHEMISTRY; REVIEW; SLEEP DISORDER; SLEEP LOSS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PRODRUGS; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 34548426119     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Testa B: Prodrug research: Futile or fertile? Biochem Pharmacol (2004) 68(11):2097-2106. • Provides an excellent general review covering many aspects of prodrugs.
2. Ettmayer P, Amidon GL, Clement B, Testa B: Lessons learned from marketed and investigational pro-drugs. J Med Chem (2004) 47(10):2393-2404.
3. Fujiwara T: Fosfluconazole (prodif intravenous solution), a therapeutic drug for deep-seated mycosis, that allows reduction in volume load, bolus injection: Basic and clinical aspects. Jap Pharm Ther (2005) 33(4):267-302.
4. Beaumont K, Webster R, Gardner I, Dack K: Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: Challenges to the discovery scientist. Curr Drug Metab (2003) 4(6):461-485. •• Provides a comprehensive listing and discussion of ester prodrugs, and enhancement of permeability.
5. Palm K, Sternberg P, Luthman K, Artursson P: Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm Res (1997) 14(5):568-571.
6. George A: The design and molecular modelling of CNS drugs. Curr Opin Drug Discovery Dev (1999) 2(4):286-292.
7. Clark DE: Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena 1. Prediction of intestinal absorption. J Pharm Sci (1999) 88(8):807-814.
8. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP: Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res (1999) 16(10):1514-1519.
9. Ertl P, Rohde B, Selzer P: Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem (2000) 43(20):3714-3717.
10. Thwaites DT, Cavet M, Hirst BH, Simmons NL: Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. Br J Pharmacol (1995) 114(5):981-986.
11. Ranadive SA, Chen AX, Serajuddin AT: Relative lipophilicities and structure-pharmacological considerations of various angiotensin-converting (ACE) inhibitors. Pharm Res (1992) 9(11):1480-1486.
12. Yan L, Guo T, Yan M: Studies on the intestinal absorption of famciclovir in rats. Jiefangjun Yaoxue Xuebao (2006) 22(5):332-335.
13. Beauchamp LM, Orr GF, De Miranda P, Burnette T, Krenitsky TA: Amino acid ester prodrugs of acyclovir. Antiviral Chem Chemother (1992) 3(33):157-164.
14. Nielson CU, Våbenø J, Andersen R, Brodin B, Steffansen B: Recent advances in therapeutic applications of human peptide transporters. Expert Opin Ther Patents (2005) 15(2):153-166.
15. Smith DA, Schmid EF: Drug withdrawals and the lessons within. Curr Opin Drug Discovery Dev (2006) 9(1):38-46.
16. Revill P, Bolos J, Serradell N, Bayes M: Gabapentin enacarbil. Drugs Future (2006) 31(9):771-777.
17. Liederer BM, Borchardt RT: Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci (2006) 95(6):1177-1195.
18. Yamazaki M, Suzuki H, Sugiyama Y: Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res (1996) 13(4):497-513.
19. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, Pang KS: Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharm Exp Ther (2006) 318(1):395-402.
20. Han Y-H, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y: Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/ MRP2). Pharm Res (2001) 18(5):579-586.
21. Voutsadakis IA: Gemtuzumab ozogamicin (CMA-676, mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anticancer Drugs (2002) 13(7):685-692.
22. Fenton C, Perry CM: Gemtuzumab ozogamicin: A review of its use in acute myeloid leukaemia. Drugs (2005) 65(16):2405-2427.
23. Gordon LI: Gemtuzumab ozogamicin (mylotarg) and hepatic venoocclusive disease: Take two acetaminophen, and.... Bone Marrow Transplant (2001) 28(9):811-812.
24. Paliouras M, Borgono C, Diamandis EP: Human tissue kallikreins: The cancer biomarker family. Cancer Lett (2007) 249(1):61-79.
25. Chen L, Gangwar S, Pan C, Rao C, Sufi B, Boyd S, Huber M, Sattari P, Do M, Dai R, Chong C et al: A novel duocarmycin-analog based prodrug, delivered as an antibody drug conjugate for targeted cancer therapy. 232nd ACS National Meeting, San Francisco, CA, USA (2006).
26. Brady SF, Pawluczyk JM, Lumma PK, Feng DM, Wai JM, Jones R, DeFeo-Jones D, Wong BK, Miller-Stein C, Lin JH, Oliff A et al: Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity. J Med Chem (2002) 45(21):4706-4715.
27. Janssen S, Jakobsen CM, Rosen DM, Ricklis RM, Reineke U, Christensen SB, Lilja H, Denmeade SR: Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Mol Cancer Ther (2004) 3(11):1439-1450.
28. Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR: Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate (2006) 66(4):358-368.
29. Ganesh T: Improved biochemical strategies for targeted delivery of taxoids. Bioorg Med Chem (2007) 15(11):3597-3623. • Provides a comprehensive review giving a thorough understanding of the diversity of thought and chemistry surrounding drug targeting approaches.
30. Xie H, Blättler WA: In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Expert Opin Biol Ther (2006) 6(3):281-291. • Provides a thoughtful discussion of the promise and problems of drug delivery via targeted antibodies.